Mycotic aortic aneurysm formation following intravesical BCG treatment for transitional cell carcinoma of the bladder

BMJ Case Rep. 2021 Nov 23;14(11):e246389. doi: 10.1136/bcr-2021-246389.

Abstract

Mycotic aneurysms are rare and if left untreated, can have devastating outcomes. In this case, a 72-year-old man presented to hospital with fevers, night sweats and abdominal pain. A CT scan revealed the development an infrarenal pseudoaneurysm over the course of 8 weeks, increasing from 2.8 cm to a 3.1 cm. The aneurysm was not present on a CT scan performed 6 months earlier. The patient underwent an emergency endovascular repair of the aortic aneurysm (EVAR) and was placed on broad-spectrum antibiotics. Intra-aortic blood cultures aspirated adjacent to the aneurysm and tissue biopsy confirmed tuberculosis bovis as the cause of the mycotic aneurysm. The patient had been treated with intravesical BCG for transitional cell carcinoma of the bladder several months prior. The patient was treated with an extended course of antituberculosis medication. He recovered well and was back to his baseline function within weeks.

Keywords: drugs: infectious diseases; infections; interventional radiology; urinary and genital tract disorders; vascular surgery.

Publication types

  • Case Reports

MeSH terms

  • Administration, Intravesical
  • Aged
  • Aneurysm, Infected* / diagnostic imaging
  • Aneurysm, Infected* / drug therapy
  • Aneurysm, Infected* / etiology
  • Antitubercular Agents / therapeutic use
  • Aortic Aneurysm*
  • Aortic Aneurysm, Abdominal* / diagnostic imaging
  • Aortic Aneurysm, Abdominal* / drug therapy
  • Aortic Aneurysm, Abdominal* / surgery
  • BCG Vaccine / adverse effects
  • Carcinoma, Transitional Cell* / drug therapy
  • Humans
  • Male
  • Urinary Bladder Neoplasms* / drug therapy

Substances

  • Antitubercular Agents
  • BCG Vaccine